SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
of Report (Date of earliest event reported):
(Exact Name of Company as Specified in Charter)
(State or Other Jurisdiction
(Commission File Number)
InMed Pharmaceuticals Inc.
|(Address of Principal Executive Offices)||(Zip Code)|
telephone number, including area code:
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||
|Name of each exchange|
on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events
On October 27, 2021, InMed Pharmaceuticals Inc. filed an Amended Notice of Meeting & Record Date relating to its 2021 annual meeting of shareholders on the System for Electronic Document Analysis and Retrieval (“SEDAR”) in Canada.
The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
The following exhibits shall be deemed to be furnished, and not filed:
|99.1||SEDAR filing submitted October 27, 2021|
|104||Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|INMED PHARMACEUTICALS INC.|
|Date: October 27, 2021||By:||/s/ Bruce Colwill|
Chief Financial Officer
|510 Burrard St, 3rd Floor Vancouver|
|Date: October 27, 2021||BC, V6C 3B9|
To: All Canadian Securities Regulatory Authorities
Subject: INMED PHARMACEUTICALS INC.
We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer:
|Meeting Type :||Annual General Meeting|
|Record Date for Notice of Meeting :||October 28, 2021|
|Record Date for Voting (if applicable) :||October 28, 2021|
|Beneficial Ownership Determination Date :||October 28, 2021|
|Meeting Date :||December 17, 2021|
|Meeting Location (if available) :||Vancouver, BC|
|Issuer sending proxy related materials directly to NOBO:||Yes|
|Issuer paying for delivery to OBO:||No|
|Notice and Access (NAA) Requirements:|
|NAA for Beneficial Holders||Yes|
|Beneficial Holders Stratification Criteria:||Not Applicable|
|NAA for Registered Holders||Yes (AMENDED)|
|Registered Holders Stratification Criteria:||Not Applicable (AMENDED)|
Voting Security Details:
Agent for INMED PHARMACEUTICALS INC.